The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles.
Author
Webb, Gabriela MLi, Shengbin
Mwakalundwa, Gwantwa
Folkvord, Joy M
Greene, Justin M
Reed, Jason S
Stanton, Jeffery J
Legasse, Alfred W
Hobbs, Theodore
Martin, Lauren D
Park, Byung S
Whitney, James B
Jeng, Emily K
Wong, Hing C
Nixon, Douglas F
Jones, R Brad
Connick, Elizabeth
Skinner, Pamela J
Sacha, Jonah B
Affiliation
Univ Arizona, Div Infect DisIssue Date
2018-01-23
Metadata
Show full item recordPublisher
AMER SOC HEMATOLOGYCitation
The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles. 2018, 2 (2):76-84 Blood AdvJournal
Blood advancesRights
© 2018 by The American Society of Hematology.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Sequestering of latent HIV in follicular helper T cells within B-cell follicles that largely exclude cytotoxic T cells is a major barrier to cellular immune-based approaches to eradicate HIV. Here, we show that the clinical-grade human interleukin-15 (IL-15) superagonist ALT-803 activates and redirects simian immunodeficiency virus (SIV)-specific CD8+ T cells from the peripheral blood into B-cell follicles. In agreement with the increased trafficking of SIV-specific cytotoxic T cells to sites of cryptic viral replication, lymph nodes of elite controlling macaques contained fewer cells expressing SIV RNA or harboring SIV DNA post-ALT-803 treatment. These data establish ALT-803 as an immunotherapeutic for HIV and other chronic viral pathogens that evade host immunity by persisting in B-cell follicles.ISSN
2473-9537PubMed ID
29365313Version
Final published versionSponsors
National Institutes of Health (NIH) from the National Institute of Allergy and Infectious Diseases (NIAID) [R21 All 28970-01A1]; National Institutes of Health (NIH) from the NIH Office, and Martin Delaney BELIEVE collaborator NIAID award [P51 OD011092, UM1A1126617]; National Institute on Drug Abuse, National Institute of Mental Health, and National Institute of Neurological Disorders and Strokeae974a485f413a2113503eed53cd6c53
10.1182/bloodadvances.2017012971
Scopus Count
Collections
Related articles
- Simian Immunodeficiency Virus-Producing Cells in Follicles Are Partially Suppressed by CD8+ Cells In Vivo.
- Authors: Li S, Folkvord JM, Rakasz EG, Abdelaal HM, Wagstaff RK, Kovacs KJ, Kim HO, Sawahata R, MaWhinney S, Masopust D, Connick E, Skinner PJ
- Issue date: 2016 Dec 15
- The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques.
- Authors: Webb GM, Molden J, Busman-Sahay K, Abdulhaqq S, Wu HL, Weber WC, Bateman KB, Reed JS, Northrup M, Maier N, Tanaka S, Gao L, Davey B, Carpenter BL, Axthelm MK, Stanton JJ, Smedley J, Greene JM, Safrit JT, Estes JD, Skinner PJ, Sacha JB
- Issue date: 2020 Mar
- Associations of Simian Immunodeficiency Virus (SIV)-Specific Follicular CD8(+) T Cells with Other Follicular T Cells Suggest Complex Contributions to SIV Viremia Control.
- Authors: Rahman MA, McKinnon KM, Karpova TS, Ball DA, Venzon DJ, Fan W, Kang G, Li Q, Robert-Guroff M
- Issue date: 2018 Apr 15
- Spatial alterations between CD4(+) T follicular helper, B, and CD8(+) T cells during simian immunodeficiency virus infection: T/B cell homeostasis, activation, and potential mechanism for viral escape.
- Authors: Hong JJ, Amancha PK, Rogers K, Ansari AA, Villinger F
- Issue date: 2012 Apr 1
- CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection.
- Authors: Pampusch MS, Abdelaal HM, Cartwright EK, Molden JS, Davey BC, Sauve JD, Sevcik EN, Rendahl AK, Rakasz EG, Connick E, Berger EA, Skinner PJ
- Issue date: 2022 Feb
